Department of Neuroscience, Reproductive Science and Odontostomatology, University of Naples Federico II, Naples, Italy.
ANDROFERT, Andrology and Human Reproduction Clinic, Campinas, Brazil.
Reprod Biol Endocrinol. 2019 Feb 6;17(1):18. doi: 10.1186/s12958-019-0460-4.
To study the role of recombinant human LH supplementation in women with hypo-response to ovarian stimulation.
We performed a systematic review and meta-analysis of prospective clinical trials in which recombinant FSH monotherapy protocols were compared with LH-supplemented protocols in hypo-responders. A search was conducted of the Scopus, MEDLINE databases without time or language restrictions. Primary outcome was clinical pregnancy rate.
Significantly higher clinical pregnancy rates (odds ratio: 2.03, P = 0.003), implantation rates (odds ratio: 2.62, P = 0.004) and number of oocytes retrieved (weight mean differences: 1.98, P = 0.03) were observed in hypo-responders supplemented with recombinant LH versus hypo-responders who underwent FSH monotherapy. No differences in terms of mature oocytes or miscarriage rates were found between the two groups.
In conclusion, our analysis confirms that women with a hypo-response to exogenous gonadotropins might benefit from LH supplementation. However, more trials are required before a definitive conclusion can be drawn.
研究重组人 LH 补充在卵巢刺激反应低下的女性中的作用。
我们对前瞻性临床试验进行了系统评价和荟萃分析,其中重组 FSH 单药治疗方案与 LH 补充方案在低反应者中的比较。在 Scopus 和 MEDLINE 数据库中进行了无时间和语言限制的检索。主要结局是临床妊娠率。
在接受重组 LH 补充的低反应者中,临床妊娠率(优势比:2.03,P=0.003)、着床率(优势比:2.62,P=0.004)和获卵数(加权均数差异:1.98,P=0.03)显著高于仅接受 FSH 单药治疗的低反应者。两组间成熟卵母细胞或流产率无差异。
总之,我们的分析证实,对外源性促性腺激素反应低下的女性可能受益于 LH 补充。然而,需要更多的试验才能得出明确的结论。